covid-19 – Page 3 – Retraction Watch

French hydroxychloroquine-COVID-19 study withdrawn

The authors of a preprint on use of hydroxychloroquine — the controversial drug heavily promoted by, and now apparently taken by, President Trump, at least for a few more days — along with azithromycin for COVID-19 have withdrawn the paper.

The preprint, “Hydroxychloroquine plus azithromycin: a potential interest in reducing in-hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)?” was posted to medRxiv on May 11 by authors at Hopital Raymond Poincare, and sometime yesterday replaced with this statement:

Covid-19 and sex? Rapid-fire acceptance leads to hasty withdrawal of paper

The Journal of the American Academy of Dermatology has taken down a letter on whether people should abstain from sex during the coronavirus pandemic, but the editor says the article is not being retracted.

Meanwhile, researchers in France have retracted a paper in which they’d claimed to have found replication of the virus that causes Covid-19 in the dialysis fluid of a patient with kidney disease. Again, hasty publication appears to be involved. We’ve been tracking retractions of Covid-19 articles on our website, and, let’s just say, the list is almost certainly a trailing indicator of the robustness of the science here — as it is with retractions during any period.

Back to the letter. “COVID-19: Should sexual practices be discouraged during the pandemic?” was written by ZhiQiang Yin, of the Department of Dermatology at the First Affiliated Hospital of Nanjing Medical University, in China. Yin submitted the article on April 14. The journal accepted it on the 16th and published it on April 30th.

According to the notice:

‘Aggressive’ COVID-19 strains: What it takes to correct a flawed paper

A group of researchers in Scotland have taken aim at a study published in early March which reported surprising findings on the genetics of the SARS-CoV-2 virus responsible for the Covid-19 pandemic.

But the story of what it took to correct the record about the paper is likely to be all too familiar to those who attempt such feats. It involved a blog post and a new paper — neither of which appeared on the site of the original journal that published the work, and neither of which is seeing the kind of attention paid to the original article.

The paper, “On the origin and continuing evolution of SARS-CoV-2,” appeared in National Science Review, published by Oxford Academic. According to the abstract:

Authors to correct influential Imperial College COVID-19 report after learning it cited a withdrawn preprint

A March paper by researchers at Imperial College London that, in the words of the Washington Post, “helped upend U.S. and U.K. coronavirus strategies,” cited a preprint that had been withdrawn.

Retraction Watch became aware of the issue after being contacted by a PubPeer commenter who had noted the withdrawal earlier this month. Following questions from Retraction Watch this weekend, the authors said they plan to submit a correction.

In March, the New York Times wrote:

Elsevier investigating hydroxychloroquine-COVID-19 paper

Elsevier has weighed in on the handling of a controversial paper about the utility of hydroxychloroquine to treat Covid-19 infection, defending the rigor of the peer review process for the article in the face of concerns that the authors included the top editor of the journal that published the work.

On April 3, as we reported, the International Society of Antimicrobial Chemotherapy issued an expression of concern (without quite calling it that) about the paper, which had appeared in March in the International Journal of Antimicrobial Agents, which the ISAC publishes, along with Elsevier. According to the society, the article, by the controversial French scientist Didier Raoult, of the University of Marseille, and colleagues:

Hydroxychloroquine-COVID-19 study did not meet publishing society’s “expected standard”

The paper that appears to have triggered the Trump administration’s obsession with hydroxychloroquine as a treatment for infection with the novel coronavirus has received a statement of concern from the society that publishes the journal in which the work appeared.

The April 3, 2020, notice, from the International Journal of Antimicrobial Agents, states that the March 20 article, “Hydroxychloroquine and azithromycin as a treatment of Covid-19: results of an open-label non-randomized clinical trial”

Share this:

Share this:

Share this:

Share this:

Share this:

Share this: